Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C2H6Na2O7P2 · xH2O
CAS Number:
Molecular Weight:
249.99 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
231-025-7
MDL number:
Product Name
Etidronate disodium hydrate, ≥97% (NMR), solid
InChI key
GWBBVOVXJZATQQ-UHFFFAOYSA-L
InChI
1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
SMILES string
[Na+].[Na+].CC(O)(P(O)([O-])=O)P(O)([O-])=O
assay
≥97% (NMR)
form
solid
color
white
mp
>300 °C
solubility
H2O: ≥10 mg/mL
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Bisphosphonate antiresorptive agent. Less potent inhibitor of farnesyl diphosphate synthase (IC50 = 80 μM) as compared to the nitrogen containing bisphosphonates
Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates.
Application
Etidronate disodium hydrate has been used in the synthesis of bisphosphonate derivatives of adenosine triphosphate (ATP)by T4 RNA ligase. It has also been sued to inhibit human farnesyl diphosphate synthase (FDPS).
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase
Sillero M A G, et al.
Febs Letters, 580(24), 5723-5727 (2006)
Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway
Su J and Huang M
European Journal of Pharmacology, 841, 75-81 (2018)
Isoprenoids increase bovine endometrial stromal cell tolerance to the cholesterol-dependent cytolysin from Trueperella pyogenes
Griffin S, et al.
Biology of Reproduction (2018)
M R McClung et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(1), 301-310 (2012-10-20)
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy
Siyoung Kim et al.
European journal of pharmacology, 699(1-3), 14-22 (2012-12-04)
Nitrogen-containing bisphosphonates (NBPs) have greater anti-bone-resorptive effects than non-nitrogen-containing bisphosphonates (non-NBPs). Hence, NBPs are the current first-choice drug for osteoporosis. However, NBPs carry a risk of osteonecrosis of jaws. Some animal and human studies suggest that non-NBPs may have anti-bone-resorptive
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service